ARTICLE | Clinical News
Toremifene citrate regulatory update
March 9, 2009 7:00 AM UTC
GTx said FDA gave an NDA for toremifene 80 mg to prevent bone fractures in men with prostate cancer on androgen deprivation therapy a standard review, resulting in a PDUFA date of Oct. 30. GTx had req...